Top Markets
#1 The Black Bull The Black Bull +22.59%
#2 EXOD EXOD +22.08%
#3 SSV Network SSV Network +21.25%
#4 XPIN Network XPIN Network +21.09%
#5 Useless Coin Useless Coin +20.60%
#6 Ore Ore +20.14%
#7 GALA GALA +19.48%
#8 Wrapped XPL Wrapped XPL +18.69%
#9 Plasma Plasma +18.68%
#10 Unit Plasma Unit Plasma +18.68%
Coin of the day
The Black Bull The Black Bull
Settings
Language
ENGLISH
Currency
USD
Theme
Arovella Therapeutics Limited Arovella Therapeutics Limited

Arovella Therapeutics Limited

ALA
Rank in Stocks #24892
Arovella Therapeutics Limited, an Australian biotechnology firm, is dedicated... Arovella Therapeutics Limited, an Australian biotechnology firm, is dedicated to developing therapeutic solutions for oncology and central nervous system afflictions, operating both domestically and internationally. Its pipeline features several key assets, including ZolpiMist, an oral spray formulation of zolpidem tartrate for the treatment of short-term insomnia, commercially known by brands such as Ambien or Stilnox. The company is also advancing an invariant natural killer T (iNKT) cell therapy platform specifically designed to target blood cancers. Furthermore, Arovella employs OroMist, an oro-mucosal technology enabling the delivery of various drug classes through absorption in the oral cavity via the cheeks, gums, tongue, or mouth floor, and is developing Anagrelide for cancer treatment. Beyond these, the company is engaged in creating oral sprays to address conditions like migraine headaches, motion sickness, and drug-resistant epilepsy. Arovella maintains a research collaboration agreement with Imperial College London. Established in 1999 and based in Osborne Park, Australia, the company was formerly known as Suda Pharmaceuticals Ltd before rebranding to Arovella Therapeutics Limited in October 2021.
Share Price
$0.04584351
Market Cap
$55.42M
Change (1 day)
1.56%
Change (1 year)
-16.04%
Country
AU
Trade Arovella Therapeutics Limited (ALA)

Category

Healthcare
P/E ratio for Arovella Therapeutics Limited (ALA)
P/E ratio as of 2026 TTM: 0
According to Arovella Therapeutics Limited latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Arovella Therapeutics Limited from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.